| Basics |
Dynavax Technologies Corporation
Dynavax Technologies Corp is a clinical-stage biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor ("TLR") stimulation.
|
| IPO Date: |
February 19, 2004 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$1.28B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.22 | 2.99%
|
| Avg Daily Range (30 D): |
$0.14 | 1.34%
|
| Avg Daily Range (90 D): |
$0.16 | 1.56%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.36M |
| Avg Daily Volume (30 D): |
1.43M |
| Avg Daily Volume (90 D): |
1.36M |
| Trade Size |
| Avg Trade Size (Sh.): |
181 |
| Avg Trade Size (Sh.) (30 D): |
83 |
| Avg Trade Size (Sh.) (90 D): |
85 |
| Institutional Trades |
| Total Inst.Trades: |
4,592 |
| Avg Inst. Trade: |
$2.38M |
| Avg Inst. Trade (30 D): |
$2.14M |
| Avg Inst. Trade (90 D): |
$2.17M |
| Avg Inst. Trade Volume: |
.19M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.94M |
| Avg Closing Trade (30 D): |
$2.46M |
| Avg Closing Trade (90 D): |
$2.67M |
| Avg Closing Volume: |
249.31K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$-.34
|
$.23
|
$.16
|
|
Diluted EPS
|
$-.37
|
$.21
|
$.14
|
|
Revenue
|
$ 330.51M
|
$ 94.88M
|
$ 95.44M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -43.4M
|
$ 26.93M
|
$ 18.72M
|
|
Operating Income / Loss
|
$ 10.44M
|
$ 21.27M
|
$ 14.43M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ 40.94M
|
$ 61.15M
|
$ 47.41M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Nov 10, 2014:
1:10
|
|
|
|
